1 |
Sakurai, K., J. P. Zou, N. I. Torres, J. R. Tschetter, H. S. Kim, and G. M. Shearer. 2002. Study of the effect of indoleamine 2,3-dioxygenase on murine mixed lymphocyte reactions and skin allograft rejection. Transplant. Proc. 34, 3271-3273.
DOI
|
2 |
Sakurai, K., J. Zhou, J. Tschetter, J. Ward, and G. Shearer. 2002. Effect of indoleamine 2,3-dioxygenase on induction of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 129, 186-196.
DOI
|
3 |
Schwarcz, R. 2004. The kynurenine pathway of tryptophan degradation as a drug target. Curr. Opin. Pharmacol. 4, 12-17.
DOI
|
4 |
Seo, S. K., J. H. Choi, Y. H. Kim, W. J. Kang, H. Y. Park, J. H. Suh, B. K. Choi, D. S. Vinay, and B. S. Kwon. 2004. 4-1BB-mediated immunotherapy of rheumatoid arthritis. Nat. Med. 10, 1088-1094.
DOI
|
5 |
Shimizu, T., S. Nomiyama, F. Hirata, and O. Hayaishi. 1978. Indoleamine 2,3-dioxygenase: purification and some properties. J. Biol. Chem. 253, 4700-4706.
|
6 |
Taylor, M. W. and G. Feng. 1991. Relationship between IFN-, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB. J. 5, 2516-2522.
|
7 |
Hayashi, T., L. Beck, C. Rossetto, X. Gong, O. Takikawa, K. Takabayashi, D. A. Carson, and E. Raz. 2004. Inhibition of experimental asthma by indoleamine 2,3-dioxygenase. J. Clin. Invest. 114, 270-279.
DOI
|
8 |
Hayashi, T., J. H. Mo, X. Gong, C. Rossetto, A. Jang, L. Beck, G. I. Elliott, I. Kufareva, R. Abagyan, D. H. Broide, J. Lee, and E. Raz. 2007. 3-Hydroxyanthranilic acid inhibits PDK1 activation and suppresses experimental asthma by inducing T cell apoptosis. Proc. Natl. Acad. Sci. USA 104, 18619-18624.
DOI
|
9 |
Janssen, E. M., N. M. Droin, E. E. Lemmens, M. J. Pinkoski, S. J. Bensinger, B. D. Ehst, T. S. Griffith, D. S. Green, and S. P. Schoenberer. 2005. CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death. Nature 434, 88-93.
DOI
|
10 |
Jeremias, I., I. Herr, T. Boehler, and K. M. Debatin. 1998. TRAIL/Apo-2-ligand-induced apoptosis in human T cells. Eur. J. Immunol. 28, 143-152.
DOI
|
11 |
Kotzin, B. L., D. Y. Leung, J. Kappler, and P. Marrack. 1993. Superantigens and their potential role in human disease. Adv. Immunol. 54, 99-166.
DOI
|
12 |
Lee, S. M., Y. S. Lee, J. H. Choi, S. G. Park, I. W. Choi, Y. D. Joo, W. S. Lee, J. N. Lee, I. H. Choi, and S. K. Seo. 2010. Tryptophan metabolite 3-hydroxyanthranilic acid selectively induces activated T cell death via intracellular GSH depletion. Immunol. Lett. 132, 53-60.
DOI
|
13 |
Mellor, A. L. and D. H. Munn. 2004 IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat. Rev. Immunol. 4, 762-774.
DOI
|
14 |
Muller, A. J., J. B. DuHadaway, P. S. Donover, E. Sutanto-Ward, and G. C. Prendergast. 2005. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat. Med. 11, 312-319.
DOI
|
15 |
Gura, T. 1997. How TRAIL kills cancer cells, but not normal cells. Science 277, 768.
DOI
|
16 |
Alexander, A. M., M. Crawford, S. Bertera, W. A. Rudert, O. Takikawa, P. D. Robbins, and M. Trucco. 2002. Indoleamine 2,3-dioxygenase expression in transplanted NOD Islets prolongs graft survival after adoptive transfer of diabetogenic splenocytes. Diabetes 51, 356-365.
DOI
|
17 |
Fallarino, F., U. Grohmann, C. Vacca, R. Bianchi, C. Orabona, A. Spreca, M. C. Fioretti, and P. Puccetti. 2002. T cell apoptosis by tryptophan catabolism. Cell Death Differ. 9, 1069-1077.
DOI
|
18 |
Frumento, G., R. Rotondo, M. Tonetti, G. Damonte, U. Benatti, and G. B. Ferrara. 2002. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J. Exp. Med. 196, 459-468.
DOI
|
19 |
Grohmann, U., F. Fallarino, R. Bianchi, C. Orabona, C. Vacca, M. C. Fioretti, and P. Puccetti. 2003. A defect in tryptophan catabolism impairs tolerance in nonobese diabetic mice. J. Exp. Med. 198, 153-160.
DOI
|
20 |
Terness, P., T. M. Bauer, L. Rose, C. Dufter, A. Watzlik, H. Simon, and G. Opelz. 2002. Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. J. Exp. Med. 196, 447-457.
DOI
|
21 |
Uyttenhove, C., L. Pilotte, I. Theate, V. Stroobant, D. Colau, N. Parmentier, T. Boon, and B. J. Van den Eynde. 2003. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med. 9, 1269-1274.
DOI
|
22 |
Vidalain, P. O., O. Azocar, C. Rabourdin-Combe, and C. Servet-Delprat. 2001. Measle virus-infected dendritic cells develop immunosuppressive and cytotoxic activities. Immunobiology. 204, 629-638.
DOI
|
23 |
Platten, M., P. P. Ho, S. Youssef, P. Fontoura, H. Garren, E. M. Hur, R. Gupta, L. Y. Lee, B. A. Kidd, W. H. Robinson, R. A. Sobel, M. L. Selley, and L. Steinman. 2005. Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite. Science 310, 850-855.
DOI
|
24 |
Wiley, S. R., K. Schooley, P. J. Smolak, W. S. Din, C. P. Huang, J. K. Nicholl, G. R. Sutherland, T. D. Smith, C. Rauch, and C. A. Smith. 1995. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3, 673-682.
DOI
|
25 |
Munn, D. H., M. D. Sharma, B. Baban, H. P. Harding, Y. Zhang, D. Ron, and A. L. Mellor. 2005. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity 22, 633-642.
DOI
|
26 |
Munn, D. H., M. Zhou, J. T. Attwood, I. Bondarev, S. J. Conway, B. Marshall, C. Brown, and A. L. Mellor. 1998. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281, 1191-1193.
DOI
|